Pyoderma Trials in Disease

Study on Short vs. Standard Amoxicillin Treatment for Adults with Lower Limb Erysipelas

This clinical trial is investigating whether a shorter course of antibiotic treatment is just as effective as the standard longer course for treating erysipelas, a bacterial skin infection that commonly affects the lower legs. The infection causes the skin to become bright red, swollen, warm, and painful, often with a clearly defined border. Patients may also experience fever, chills, and general discomfort.

Main inclusion criteria:

• Adults aged 18 years or older
• Recent signs of leg erysipelas lasting 5 days or less, including warmth, redness, swelling, and pain
• Recent fever or feverish feeling lasting 5 days or less, or a measured fever of 38°C or higher
• A severity score of 3 or more based on swelling, redness, and pain
• No history of erysipelas in the past 12 months
• No skin tissue death, crackling sensations under the skin, blisters, or solid purple spots
• Participation in a social security program
• Written consent after understanding the study details

Main exclusion criteria:

• Individuals under 18 years of age
• Those without a diagnosis of erysipelas in the lower limbs
• Members of vulnerable populations, such as pregnant women, children, or those unable to provide informed consent

Focus and goals:

The trial compares two treatment durations: a short course of 5 days versus a standard course of 10 days. Participants are randomly assigned to one of these groups and take amoxicillin orally at a dose of 50 mg per kilogram of body weight. The primary goal is to achieve complete remission by day 12, meaning the disappearance of fever, pain, warmth, redness, and swelling without the need for additional antibiotics. The study also monitors the rate of infection recurrence and any side effects experienced during and after treatment.

The trial follows a structured timeline. After confirming eligibility and obtaining consent, participants undergo an initial assessment to evaluate the severity of their symptoms. During the treatment phase, they take amoxicillin according to their assigned group. Symptoms are monitored throughout to track recovery, and a final evaluation confirms whether complete remission has been achieved and records any recurrence or adverse events.

Investigational drug:

The trial uses amoxicillin, a semi-synthetic penicillin-type antibiotic. Amoxicillin works by blocking the formation of bacterial cell walls, which leads to the destruction of the bacteria causing the infection. It is administered orally in tablet or capsule form and is a well-established antibiotic widely used in medical practice. The trial aims to determine if the shorter treatment duration can provide the same benefits as the longer standard course, potentially offering patients a more convenient treatment option.